Skip to content

Author

C. Peer

We have 2 of 242 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Rivaroxaban with Cobicistat or Darunavir/Cobicistat in Healthy Participants.

BACKGROUND Direct oral anticoagulants such as rivaroxaban are a feasible and convenient option for anticoagulation in people living with HIV. Here, we assess the effect of cobicistat or darunavir/cobicistat on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of rivaroxaban. METHODS This open-label, fixed...

Lilian W. Adeojo, Cheryl Pauls, Doris Z. Swaim et al. · 0 citations
Review Open access Jul 2026

Innovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development

Examples include drug repurposing, characterizing PK/PD in early phase to inform late‐phase development, population PK analysis to guide trial dosing and label recommendations, and applying M‐PBPK to predict clinical PK in organ impairment populations.

R. Oberoi, C. Peer, Ashutosh Tripathi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.